News
Monocyte Distribution Width as a New Indicator of Sepsis in High-Risk Patients
Most septic patients are first encountered in the emergency department, where sepsis detection is often delayed, partly due to a lack of effective biomarkers. The study presented below evaluated the diagnostic accuracy of monocyte distribution width in peripheral blood alone and in combination with white blood cell count evaluation for early sepsis detection.
New Hematological Biomarker for Early Diagnosis of Sepsis
Sepsis is one of the leading causes of mortality and healthcare expenditure worldwide. Early…
Interstitial Lung Processes and Their Fibrotic Progression
Interstitial lung processes (ILPs) include more than 200 clinical units that share diffuse…
Evaluation of Continuity of Care in Patients with mCRC – Baseline Characteristics of Participants in the PROMETCO Study
During this year's World Congress of the European Society for Medical Oncology (ESMO) on gastrointestinal...
Trifluridine/tipiracil in Real Clinical Practice – Current Data from Spain
Trifluridine/tipiracil is indicated for the treatment of patients with refractory metastatic colorectal...
Evaluation of Treatment Response in CLL
The size of lymph nodes, liver, spleen, blood cell counts, systemic symptoms... Changes in these indicators...
Idiopathic Pulmonary Fibrosis: Can This Disease Be Named More Precisely?
Much about idiopathic pulmonary fibrosis (IPF) is still unknown. Some experts would like to…
Brigatinib in the Therapy of ALK-Positive NSCLC in Patients Refractory to Crizotinib Therapy – Results of the Final Analysis of Clinical Studies
Previously published results of clinical studies have shown that in patients refractory to…
Brigatinib in the Therapy of ALK-Positive NSCLC – First Results of the J-ALTA Study
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity against…
Ivabradine and/or Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction
Ivabradine and sacubitril/valsartan are used in the second line of therapy for heart failure with…